Literature DB >> 16417840

Neuropathologic substrate of cerebral palsy.

Rebecca D Folkerth1.   

Abstract

Animal models have assisted in understanding the mechanisms of brain injury underlying cerebral palsy. Nevertheless, no such models replicate every aspect of the human disease. This review summarizes the classic and more recent studies of the neuropathology of human perinatal brain injury most commonly associated with cerebral palsy, for use by researchers and clinicians alike who need to analyze published animal models with respect to their fidelity to the human disorder. The neuropathology underlying cerebral palsy includes white-matter injury, known as periventricular leukomalacia, as well as germinal matrix hemorrhage with intraventricular extension, and injury to the cortex, basal ganglia, and thalamus. Each has distinctive features while sharing some risk factors, such as prematurity and/or hypoxia-ischemia in the perinatal period. Periventricular leukomalacia consists of diffuse injury of deep cerebral white matter, with or without focal necrosis. Recent work directly in human postmortem tissue has focused on the role of free radical injury, cytokine toxicity (especially in light of the epidemiologic association of periventricular leukomalacia with maternofetal infection), and excitotoxicity in the development of periventricular leukomalacia. Premyelinating oligodendrocytes, which predominate in periventricular regions during the window of vulnerability to periventricular leukomalacia (24-34 postconceptional weeks), are the targets of free radical injury, as determined by immunocytochemical markers of lipid peroxidation and protein nitration. This maturational susceptibility can be attributed in part to a relative deficiency of superoxide dismutases in developing white matter. Microglia, which respond to cytokines and to bacterial products such as lipopolysaccharide via Toll-like receptors, are increased in periventricular leukomalacia white matter and can contribute to cellular damage. Indeed, several cytokines, including tumor necrosis factor-a and interleukins 2 and 6, as well as interferon-g, have been demonstrated in periventricular leukomalacia. Preliminary work suggests a role for glutamate receptors and glutamate transporters in periventricular leukomalacia based on expression in human developing oligodendrocytes. Germinal matrix hemorrhage, with or without intraventricular hemorrhage, occurs in premature infants and can coexist with periventricular leukomalacia. Studies in human germinal matrix tissue have focused on maturation-based vascular factors, such as morphometry and expression of molecules related to the structure of the blood-brain barrier. Gray-matter injury, seen more commonly in term infants, includes cortical infarcts and status marmoratus. Subtle cortical injury overlying periventricular leukomalacia is the subject of current interest as a possible substrate for the cognitive difficulties seen in patients with cerebral palsy. In summary, it is hoped that work in human tissue, in conjunction with experimental animal models, will lead to eventual therapeutic or preventive strategies for the perinatal brain injury underlying cerebral palsy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16417840     DOI: 10.1177/08830738050200120301

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  45 in total

1.  Sulfonylurea receptor 1 in the germinal matrix of premature infants.

Authors:  J Marc Simard; Rudolph J Castellani; Svetlana Ivanova; Michael T Koltz; Volodymyr Gerzanich
Journal:  Pediatr Res       Date:  2008-12       Impact factor: 3.756

2.  Glial localization of antiquitin: implications for pyridoxine-dependent epilepsy.

Authors:  Laura A Jansen; Robert F Hevner; William H Roden; Si Houn Hahn; Sunhee Jung; Sidney M Gospe
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422

3.  Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain.

Authors:  Zhi Zhang; Bassam Bassam; Ajit G Thomas; Monica Williams; Jinhuan Liu; Elizabeth Nance; Camilo Rojas; Barbara S Slusher; Sujatha Kannan
Journal:  Neurobiol Dis       Date:  2016-06-17       Impact factor: 5.996

4.  Early Detection of Cerebral Palsy Using Sensorimotor Tract Biomarkers in Very Preterm Infants.

Authors:  Nehal A Parikh; Alexa Hershey; Mekibib Altaye
Journal:  Pediatr Neurol       Date:  2019-05-09       Impact factor: 3.372

5.  Excitability and synaptic communication within the oligodendrocyte lineage.

Authors:  Lindsay M De Biase; Akiko Nishiyama; Dwight E Bergles
Journal:  J Neurosci       Date:  2010-03-10       Impact factor: 6.167

6.  Association of impaired neuronal migration with cognitive deficits in extremely preterm infants.

Authors:  Ken-Ichiro Kubo; Kimiko Deguchi; Taku Nagai; Yukiko Ito; Keitaro Yoshida; Toshihiro Endo; Seico Benner; Wei Shan; Ayako Kitazawa; Michihiko Aramaki; Kazuhiro Ishii; Minkyung Shin; Yuki Matsunaga; Kanehiro Hayashi; Masaki Kakeyama; Chiharu Tohyama; Kenji F Tanaka; Kohichi Tanaka; Sachio Takashima; Masahiro Nakayama; Masayuki Itoh; Yukio Hirata; Barbara Antalffy; Dawna D Armstrong; Kiyofumi Yamada; Ken Inoue; Kazunori Nakajima
Journal:  JCI Insight       Date:  2017-05-18

Review 7.  Brain-immune interactions in perinatal hypoxic-ischemic brain injury.

Authors:  Bo Li; Katherine Concepcion; Xianmei Meng; Lubo Zhang
Journal:  Prog Neurobiol       Date:  2017-10-27       Impact factor: 11.685

Review 8.  Pathogenesis of cerebral white matter injury of prematurity.

Authors:  O Khwaja; J J Volpe
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2008-03       Impact factor: 5.747

Review 9.  Hypoxic-ischemic encephalopathy in the term infant.

Authors:  Ali Fatemi; Mary Ann Wilson; Michael V Johnston
Journal:  Clin Perinatol       Date:  2009-12       Impact factor: 3.430

10.  Inhibition of gelatinase activity reduces neural injury in an ex vivo model of hypoxia-ischemia.

Authors:  C C Leonardo; A A Hall; L A Collier; P E Gottschall; K R Pennypacker
Journal:  Neuroscience       Date:  2009-03-09       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.